What is the difference between adjuvant and neoadjuvant treatment for CLL

Adjuvant vs. Neoadjuvant Treatment in CLL

This is a great question, but I want to clarify something important: these terms are used differently in CLL than in solid tumors (like breast or colon cancer), so the distinction works a bit differently.

How These Terms Typically Work

Neoadjuvant treatment = therapy given BEFORE the main treatment (usually surgery) Adjuvant treatment = therapy given AFTER the main treatment to reduce recurrence risk

In CLL, the Approach is Different

According to the NCCN Guidelines for Chronic Lymphocytic Leukemia, CLL treatment doesn't typically follow the "surgery-first" model that defines adjuvant/neoadjuvant in solid tumors. Instead:

• CLL is treated with systemic therapy (drugs that circulate through your whole body) rather than surgery as the primary approach
• Treatment decisions are based on whether you have early-stage disease (watch and wait) or advanced disease requiring treatment
• When treatment is needed, doctors select from targeted therapies (like BTK inhibitors), chemotherapy combinations, or newer approaches—not based on whether it's "before" or "after" surgery

What You Might Hear Instead in CLL

Debulking therapy: Sometimes doctors use a BTK inhibitor first to reduce tumor burden (the amount of cancer cells) before starting another treatment like venetoclax. This is mentioned in the NCCN Guidelines as a strategy to reduce the risk of tumor lysis syndrome (TLS)—a serious condition where cancer cells break down too quickly.

Bridge therapy: Treatment given temporarily to control disease while waiting for another treatment (like a stem cell transplant).

Questions to Ask Your Oncologist

1. What is my current disease stage, and does it require treatment now?
2. If I need treatment, what is the recommended first-line approach for my specific situation?
3. Will any treatments be used sequentially (one after another), and if so, why?
4. Are there any clinical trials that might be appropriate for me?

The NCCN Guidelines emphasize that treatment selection for CLL depends on factors like your age, fitness level, specific genetic markers (like del(17p) or TP53 mutations), and whether your disease has been treated before—not on the adjuvant/neoadjuvant framework.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.